Sign In
Buy HALO
$82.54
-0.760 (-0.91%)
At Close: Jul 31, 2026
Halozyme's Elektrofi Deal: Site-Of-Care Optionality (Rating Upgrade)
04:06am, Monday, 15'th Dec 2025
Halozyme is upgraded to a near-term Buy, driven by robust 2025–2028 royalty visibility and conservative valuation. HALO's acquisition of Elektrofi (Hypercon) extends IP into the 2040s, offering opti
Federated Hermes Inc. Has $19.15 Million Holdings in Halozyme Therapeutics, Inc. $HALO
04:20am, Thursday, 11'th Dec 2025
Federated Hermes Inc. boosted its stake in Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 2.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commi
Halozyme Therapeutics, Inc. $HALO Shares Sold by Gabelli Funds LLC
05:02am, Wednesday, 10'th Dec 2025
Gabelli Funds LLC trimmed its holdings in Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 96.6% during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. Th
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
10:46am, Tuesday, 09'th Dec 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Jim Lang Elected to Halozyme's Board of Directors
04:05pm, Monday, 08'th Dec 2025
SAN DIEGO , Dec. 8, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ("Halozyme") today announced the election of Jim Lang to its Board of Directors. Mr. Lang brings more than 30 ye
American Century Companies Inc. Sells 762,886 Shares of Halozyme Therapeutics, Inc. $HALO
04:16am, Sunday, 07'th Dec 2025
American Century Companies Inc. trimmed its position in Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 85.2% during the undefined quarter, according to the company in its most recent Form 13F filing wi
The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar.
09:30am, Saturday, 06'th Dec 2025
Halozyme Therapeutics is a leader in the subcutaneous drug delivery niche, generating gobs of free cash flow. The company faces patent cliffs ahead for its core products and is actively trying to dive
Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case
02:22pm, Thursday, 04'th Dec 2025
The Munich Regional Court ruled there was imminent infringement for Merck & Co.'s Keytruda SC in Germany related to Halozyme's MDASE patents in Europe, the San Diego company said.
Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany
01:26pm, Thursday, 04'th Dec 2025
SAN DIEGO , Dec. 4, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), announced today that a German court has granted its request for a preliminary injunction ordering Merck
Fisher Asset Management LLC Decreases Stock Position in Halozyme Therapeutics, Inc. $HALO
04:38am, Thursday, 04'th Dec 2025
Fisher Asset Management LLC decreased its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 8.6% during the undefined quarter, according to the company in its most recent filing with th
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Rating of “Moderate Buy” by Analysts
01:41am, Thursday, 04'th Dec 2025
Halozyme Therapeutics, Inc. (NASDAQ: HALO - Get Free Report) has earned a consensus rating of "Moderate Buy" from the fourteen analysts that are covering the company, Marketbeat.com reports. Seven equ
Why Is Halozyme Therapeutics (HALO) Down 2.2% Since Last Earnings Report?
12:31pm, Wednesday, 03'rd Dec 2025
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
Blueshift Asset Management LLC Makes New Investment in Halozyme Therapeutics, Inc. $HALO
04:54am, Wednesday, 03'rd Dec 2025
Blueshift Asset Management LLC acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ: HALO) during the second quarter, according to the company in its most recent filing with the Securities and
Halozyme Therapeutics, Inc. (HALO) Presents at Evercore 8th Annual Healthcare Conference Transcript
03:43pm, Tuesday, 02'nd Dec 2025
Halozyme Therapeutics, Inc. (HALO) Presents at Evercore 8th Annual Healthcare Conference Transcript
What Makes Halozyme Therapeutics (HALO) a New Buy Stock
01:01pm, Monday, 01'st Dec 2025
Halozyme Therapeutics (HALO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
